AbbVie 8-K

Summary

AbbVie debt offering to help finance its Apogee acquisition. AbbVie agreed to issue $10B principal amount of senior notes across nine tranches; the sale is expected to close on 8/18/2026, subject to customary conditions.

Key Figures

• Debt: $0.5B floating-rate notes due 2028, priced at 100% of principal; fixed-rate notes priced at 99.970% ($1B, 4.500%, 2028), 99.862% ($1.25B, 4.650%, 2030), 99.977% ($1.5B, 4.875%, 2031), 99.889% ($1.25B, 5.050%, 2033), 99.832% ($1.5B, 5.300%, 2036), 99.810% ($1B, 5.450%, 2038), 99.441% ($1.5B, 6.000%, 2056) and 99.843% ($0.5B, 6.100%, 2066) of principal.
• Net proceeds: ≈$9.93B after underwriting discounts and estimated offering expenses; intended for part of the Apogee acquisition cash payment and related costs, plus general corporate purposes, potentially including debt repayment or repurchase.
• Proceeds will reduce commitments under AbbVie’s $10B 364-day delayed-draw term loan facility arranged for the Apogee acquisition.

Investor Takeaways

• Watch for the expected 8/18/2026 closing; completion is subject to customary conditions.